ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So

Benzinga_recent_news01-17

Hedge funds don't need headlines to move — they need inflection points. ImmunityBio Inc (NASDAQ:IBRX) just delivered one. ImmunityBio stock has gone vertical, up nearly 96% year-to-date, but the real ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604399054?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/16/San-Diego--Ca--Usa---July-9--2022-Immuni.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-01-17 00:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604399054","market":"hk","top_or_hot":-1,"title":"ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So","media":"Benzinga_recent_news","content":"<div>\n<p>Hedge funds don't need headlines to move — they need inflection points. ImmunityBio Inc (NASDAQ:IBRX) just delivered one. ImmunityBio stock has gone vertical, up nearly 96% year-to-date, but the real ...</p>\n\n<a href=\"https://www.benzinga.com/markets/hedge-funds/26/01/49969034/immunitybios-700-revenue-boom-becomes-citadels-latest-i%e2%80%91told%e2%80%91you%e2%80%91so\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-17 00:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/hedge-funds/26/01/49969034/immunitybios-700-revenue-boom-becomes-citadels-latest-i%e2%80%91told%e2%80%91you%e2%80%91so><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hedge funds don't need headlines to move — they need inflection points. ImmunityBio Inc (NASDAQ:IBRX) just delivered one. ImmunityBio stock has gone vertical, up nearly 96% year-to-date, but the real ...</p>\n\n<a href=\"https://www.benzinga.com/markets/hedge-funds/26/01/49969034/immunitybios-700-revenue-boom-becomes-citadels-latest-i%e2%80%91told%e2%80%91you%e2%80%91so\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"https://www.benzinga.com/markets/hedge-funds/26/01/49969034/immunitybios-700-revenue-boom-becomes-citadels-latest-i%e2%80%91told%e2%80%91you%e2%80%91so","article_id":"2604399054","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/16/San-Diego--Ca--Usa---July-9--2022-Immuni.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/hedge-funds/26/01/49969034/immunitybios-700-revenue-boom-becomes-citadels-latest-i%e2%80%91told%e2%80%91you%e2%80%91so","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2604399054","pubTimestamp":1768579440,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Hedge funds have been anticipating a surge in ImmunityBio's revenue, which has grown by 700% year-over-year.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc.","BK4139":"生物科技"},"translate_title":"ImmunityBio 700%的收入增长成为Citadel最新的《我告诉过你》","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"Hedge funds don't need headlines to move — they need inflection points. ImmunityBio Inc (NASDAQ:IBRX) just delivered one. ImmunityBio stock has gone vertical, up nearly 96% year-to-date, but the real story isn't the stock move. It's the number behind it.\nOn Thursday, ImmunityBio reported ~$113 million in 2025 revenue, marking a staggering 700% year-over-year increase — the kind of acceleration that turns early positioning into visible validation.\nThe most important data point wasn't just the full-year figure. Fourth quarter revenue surged to $38.3 million, up 431% year-over-year, driven by the rapid commercial scaling of ImmunityBio's lead oncology therapy, Anktiva.\nIn biotech, speed matters. \nMany drugs launch slowly, struggle to gain traction, or stall entirely. Anktiva's ramp stands out because it's scaling faster than most oncology treatments at a similar stage — shifting the narrative from binary trial risk to execution and demand. That's the moment sophisticated investors wait for.\nThis surge didn't catch everyone off guard. Renaissance Technologies initiated its position in the quarter ending Sept. 30, 2025, while Ken Griffin's Citadel Advisors increased its stake by more than 40% during the same period. These weren't momentum chases — they were anticipatory bets on commercialization velocity.\nFor funds like these, the thesis wasn't about whether Anktiva would reach the market. It was about whether revenues would scale faster than consensus expected. The latest numbers suggest that the bet is starting to pay off.\nAt around $5 a share, ImmunityBio is still treated like a speculative biotech. But 700% revenue growth forces a reassessment. \nWhen early hedge fund positioning meets real sales acceleration, the market tends to shift from debating possibility to pricing pace. And once that transition begins, volatility usually cuts both ways — often with speed on the upside.\nPhoto: Shutterstock\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604399054","isCrawlerRequest":true}